MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/schizbullopen/sgag002

Медицинская библиотека · Schizophrenia bulletin open · 2026

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

Horan William P, Saucier Cory, Weiden Peter J, Claxton Amy, Marder Stephen R, Foster April M, Sauder Colin, LaGasse Kaitlin, Rucker Sloan, Jackson Kristi, Patel Tej, Sonnenberg John G, Kaul Inder

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Xanomeline and trospium chloride (formerly KarXT) is a muscarinic M1 and M4 receptor agonist recently approved for the treatment of schizophrenia in adults. Unlike all previously approved antipsychotics, it does not directly block dopamine D2 receptors. Given its novel mechanism of action, understanding patients' subjective treatment experiences, including perceived symptom changes, is clinically important.

METHODS

This is a qualitative study embedded within a larger 52-week open-label long-term safety study that investigated patient perspectives on xanomeline/trospium monotherapy in clinically stable outpatients transitioned from previous antipsychotic treatments. A subsample completed up to 2 semi-structured interviews to explore their experience-favorable or unfavorable-approximately 6 weeks (n = 70) and 6 months (n = 47) post-initiation. Thematic analysis was applied to interview transcripts.

RESULTS

At study entry, most participants reported symptoms despite ongoing antipsychotic treatment, including positive (auditory hallucinations, >80%), negative (low motivation, >70%), and cognitive (trouble concentrating, >70%) symptoms. Over 60% reported meaningful improvement in one or more symptoms within 6 weeks of starting xanomeline/trospium, increasing to about 80% by 6 months. Less than 10% reported symptom worsening at either time point. Participants described these improvements as personally meaningful, with notable benefits in daily functioning.

DISCUSSION: Participants entered this study with various persistent, burdensome schizophrenia symptoms despite ongoing treatment. Most experienced substantial and sustained symptom relief for up to 6 months after initiating xanomeline/trospium treatment. These qualitative findings highlight xanomeline/trospium's potential to provide meaningful relief across multiple symptom domains and support functional recovery. A companion report explores quality of life and medication satisfaction.

Для цитирования: Horan William P, Saucier Cory, Weiden Peter J, Claxton Amy, Marder Stephen R, Foster April M, Sauder Colin, LaGasse Kaitlin, Rucker Sloan, Jackson Kristi, Patel Tej, Sonnenberg John G, Kaul Inder. A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.. Schizophrenia bulletin open. 2026. DOI: 10.1093/schizbullopen/sgag002.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.